title: [Comparison of effects of three chemotherapy regimens for advanced non-small cell lung cancer].
abstract: OBJECTIVE
  The platinum-combination chemotherapy has been proved to be benefit to the patients with advanced non-small cell lung cancer (NSCLC), but the suitable regimen of chemotherapy has been much debated during the last decade. This study was designed to compare MIP regimen [mitomycin + ifosfamid + cisplatin], TP regimen [Taxol + cisplatin], and DP regimen [docetaxel + cisplatin] and to evaluate the efficacy of the three regimens in patients with advanced NSCLC.
  
  
  METHODS
  Ninety-two patients were enrolled in this study, 32 for MIP, 30 for TP, and 30 for DP. The characteristics of patients were comparable except there were more stage IV patients and second chemotherapy patients in DP group.
  
  
  RESULTS
  For MIP, TP, and DP groups, the objective response rates were 43.8%, 40%, and 46.7%, respectively; the median duration of survival were 11, 10, and 12 months respectively; the 1 year survival rate were 46%, 40%, and 50%, respectively. The major toxicities were bone marrow suppression, nausea, vomiting, and alopecia.
  
  
  CONCLUSIONS
  MIP, TP, and DP regimens are effective and safe chemotherapy protocols for the treatment of advanced NSCLC patients.
authors.affiliation: Department of Medical Oncology, Cancer Hospital, P. R. China. Lyc-1@21cn.com
authors.forename: Ying-cheng
authors.initials: YC
authors.lastname: Lin
authors.forename: Yi
authors.initials: Y
authors.lastname: Lin
authors.forename: Wen
authors.initials: W
authors.lastname: Lin
authors.forename: Cai-wen
authors.initials: CW
authors.lastname: Du
authors.forename: Ming-yao
authors.initials: MY
authors.lastname: Wu
authors.forename: De-rui
authors.initials: DR
authors.lastname: Li
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D043823:Taxoids; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016685:Mitomycin; D017239:Paclitaxel; D002945:Cisplatin; D007069:Ifosfamide